Summit Therapeutics has launched a new Phase 3 HARMONI-10 trial. What question is the study designed to answer, how does it fit into the company's clinical program, and what milestones or risks should investors monitor?
The FDA rejected Summit Therapeutics’ ivonescimab application after overall survival missed the target by 0.012. What did the FDA decision and trial data establish, and what options or uncertainties remain for the drug’s development?
Summit Therapeutics is down 16.47% after Akeso’s ivonescimab was rejected by the FDA, a setback reported to have spilled over to Summit. What is the connection, and what does the news imply for Summit’s development and regulatory risks?
Investors are debating whether Summit Therapeutics’ efficacy data meet the threshold for regulatory approval. What do the available data and company disclosures show, what remains uncertain, and what could change the debate?
Summit Therapeutics' ivonescimab showed breakthrough neoadjuvant lung cancer data, raising the possibility of a market worth billions of dollars. What did the data demonstrate, and what clinical or commercial questions remain before that opportunity is clearer?